tldrdailynews.com logo

Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial

1 min read
Source: Novavax
Novavax's COVID-Influenza Vaccine Candidates Demonstrate Strong Immune Response in Phase 3 Trial
Photo: Novavax
TL;DR

Novavax announced that its COVID-19-Influenza combination and stand-alone influenza vaccines elicited strong immune responses and were well tolerated in a Phase 3 trial involving adults aged 65 and older, with results comparable to existing licensed vaccines, supporting further development and potential partnerships.

Topics:businesshealth#covid-19#health#influenza#novavax#phase-3#vaccine
Share this article
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial  NovavaxView Full Coverage on Google News

Want the full story? Read the original reporting

Read on Novavax